Abstract
Psychotropic actions of cocaine are generally thought to involve its blockade of monoamine transporters leading to increased synaptic levels of monoamines, especially dopamine. Subsequent intracellular events have been less well characterized. We describe a signaling system wherein lower behavioral stimulant doses of cocaine, as well as higher neurotoxic doses, activate a cascade wherein nitric oxide nitrosylates glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to generate a complex with the ubiquitin-E3-ligase Siah1 which translocates to the nucleus. With lower cocaine doses, nuclear GAPDH augments CREB signaling, while at higher doses p53 signaling is enhanced. The drug CGP3466B very potently blocks GAPDH nitrosylation, hindering both signaling cascades and inhibits both behavioral activating and neurotoxic effects of cocaine. This system affords potentially novel approaches to the therapy of cocaine abuse.
Keywords: Addiction, CGP3466B, cocaine, GAPDH, neurotoxicity, nitric oxide, nitrosylation.
CNS & Neurological Disorders - Drug Targets
Title:Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine
Volume: 14 Issue: 6
Author(s): Maged M. Harraz and Solomon H. Snyder
Affiliation:
Keywords: Addiction, CGP3466B, cocaine, GAPDH, neurotoxicity, nitric oxide, nitrosylation.
Abstract: Psychotropic actions of cocaine are generally thought to involve its blockade of monoamine transporters leading to increased synaptic levels of monoamines, especially dopamine. Subsequent intracellular events have been less well characterized. We describe a signaling system wherein lower behavioral stimulant doses of cocaine, as well as higher neurotoxic doses, activate a cascade wherein nitric oxide nitrosylates glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to generate a complex with the ubiquitin-E3-ligase Siah1 which translocates to the nucleus. With lower cocaine doses, nuclear GAPDH augments CREB signaling, while at higher doses p53 signaling is enhanced. The drug CGP3466B very potently blocks GAPDH nitrosylation, hindering both signaling cascades and inhibits both behavioral activating and neurotoxic effects of cocaine. This system affords potentially novel approaches to the therapy of cocaine abuse.
Export Options
About this article
Cite this article as:
Harraz M. Maged and Snyder H. Solomon, Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine, CNS & Neurological Disorders - Drug Targets 2015; 14 (6) . https://dx.doi.org/10.2174/1871527314666150529150143
DOI https://dx.doi.org/10.2174/1871527314666150529150143 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases
Mini-Reviews in Medicinal Chemistry Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Bone Modulating Bioactive Natural Compounds: Review
Current Bioactive Compounds Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis
Current Gene Therapy Augmenting T Helper Cell Immunity in Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Interleukin-18: Biology and Role in the Immunotherapy of Cancer
Current Medicinal Chemistry Is Intake of Flavonoid-Based Food Supplements During Pregnancy Safe for the Developing Child? A Literature Review
Current Drug Targets Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry 1α ,25(OH)2-Vitamin D3 and 17β-Estradiol: Two Steroid Partners Acting in Skeletal Muscle
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Arsenic Trioxide Exerts Anti-lung Cancer Activity by Inhibiting Angiogenesis
Current Cancer Drug Targets Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets